ArticleJournal of orthopaedic surgery and research2026
Tibial periosteal distraction as an adjunct to percutaneous transluminal angioplasty for diabetic foot ulcers complicated by peripheral arterial disease/chronic limb-threatening ischemia: a retrospective cohort study.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDiabetic foot ulcer (DFU) complicated by peripheral arterial disease/chronic limb-threatening ischemia (PAD/CLTI) is a major cause of impaired wound healing and limb loss. In some patients, local tissue perfusion remains insufficient and wound healing is delayed even after technically successful percutaneous transluminal angioplasty (PTA). Tibial periosteal distraction (TPD) may offer incremental benefit after PTA, but direct comparative evidence supporting its role as an adjunctive strategy remains limited.
methodsThis single-center retrospective cohort study included patients with DFU and PAD/CLTI who underwent index PTA. In the adjunctive group, TPD was performed as a prespecified staged procedure within 7 days after PTA during the same hospitalization. The primary outcome was time to complete wound healing, and the key secondary outcome was 12-month amputation-free survival (AFS). Secondary outcomes included complete wound healing at 3 and 6 months, wound recurrence within 12 months, and longitudinal changes in wound area, transcutaneous oxygen pressure (TcPO₂), and ankle-brachial index (ABI).
resultsA total of 64 patients were included, with 24 in the PTA + TPD group and 40 in the PTA-alone group. PTA + TPD was associated with a shorter time to complete wound healing than PTA alone, and this association remained significant after adjustment for prespecified baseline covariates (adjusted HR, 3.90; 95% CI 2.23-6.83; P < 0.001). The 3-month complete wound healing rate was also higher in the PTA + TPD group (P = 0.016), whereas the 6-month healing rate did not differ significantly between groups (P = 0.642). Although 12-month AFS was numerically higher in the PTA + TPD group (95.8% vs 82.5%), the between-group difference was not statistically significant (P = 0.240). Linear mixed-effects models showed more favorable trajectories of wound area, TcPO₂, and ABI in the PTA + TPD group, with significant group-by-time interactions for all three outcomes (all P < 0.001). Complication rates were comparable between groups (all P > 0.05).
conclusionIn patients with DFU and PAD/CLTI, the addition of TPD after PTA was associated with faster wound healing and more favorable perfusion-related changes during follow-up. TPD may have potential value as a post-revascularization adjunct, although this requires confirmation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.